Pharma Pulse 7/23/25: Understanding Executive Orders and Trial Compliance; The Goal of Cancer Treatment

Understanding Executive Orders and Trial Compliance

In an interview with Applied Clinical Trials, Kate Gallin Heffernan, life sciences attorney, Epstein Becker Green, discussed how evolving executive orders and federal funding policies are creating confusion and heightened compliance risks for clinical research teams—particularly those working with diverse populations—emphasizing the need for accurate documentation, legal awareness, and stronger academia-industry partnerships to future-proof their research efforts.

The Goal of Cancer Treatment

In an interview with Pharmaceutical Executive, Ben Zeskind, CEO, co-founder, Immuneering, explained the company’s unique approach to cancer treatment, emphasizing that a slower, more tolerable method of tumor reduction can lead to more durable outcomes and fewer side effects—ultimately aiming to make cancer a manageable, chronic condition patients can outlive.

Shaping Pharmacy Research with Purpose and Public Impact

Omolola Adeoye-Olatunde has built a career at the intersection of pharmacy practice, public health, and policy, using community-engaged research and implementation science to advance health equity, lead pharmacist-driven studies, and develop collaborative partnerships that address social determinants of health and improve outcomes for underserved communities.

Natural Language Processing Streamlines Clinical Encounter Note Collection in Indolent Systemic Mastocytosis

A recent study demonstrated that natural language processing can efficiently analyze unstructured clinical notes in electronic medical records to identify patients with indolent systemic mastocytosis, enabling faster, more comprehensive insights into symptom burden, comorbidities, and healthcare utilization compared with traditional manual review methods.

PTSD Is Treatable, But There's No Holy Grail: Insights from Arash Javanbakht, MD

Arash Javanbakht, MD, emphasized that while PTSD is treatable, current therapies and medications remain limited, and greater progress is needed—particularly in addressing real-world functional challenges like socialization and daily activities, where traditional clinical approaches such as exposure therapy often fall short.